Translating Innovative Technology
Cadre Bioscience aims to accelerate the development of
early-stage therapeutics for multiple technology assets
cadre noun | ka-drā
a group of trained individuals that have a unifying relationship and goal
At Cadre Bioscience, we are a core group focused on development of a portfolio of early-stage therapeutic assets. Utilizing an experienced management team, accelerator lab facilities and an extensive network of consultants and collaborators we provide an alternative for innovators who want to see their therapeutic technology developed for the benefit of patients without the need to found their own company and raise capital. Cadre’s experience, infrastructure and network creates greater efficiencies, shortens timelines, and increases chances of success.
The traditional route of pursuing a commercial path for a therapeutic technology via formation of a start-up company comes with numerous challenges, notably the raising of capital, attracting suitably experienced management and creating a development plan. Often the availability of suitable business and development experience is limited, so that building a company around a single technology during the earliest stages of development is inherently inefficient. By providing a source of this experience and expertise for multiple technologies under the same umbrella, Cadre provides an attractive means for innovators to launch their technology down a path towards commercialization and providing patient benefit.
Our goal is to advance your fledgling therapeutic technology and to attract venture capital investment in order to create stand-alone companies, which can then fly the Cadre nest with their own dedicated funding, leadership and scientific team.
Bob Karr, MD
Executive Chairman & CEO
Bob Karr is a physician and scientist with over 25 years of senior executive experience in pharma and biotech, including discovery research, IND-enabling studies, clinical development and fundraising. Following roles in large pharma at G.D. Searle, Warner-Lambert and Pfizer, he served as President of Idera Pharmaceuticals in Cambridge, MA from 2005-2007 and on the Idera Board of Directors 2005-2015. Since 2008, Bob has focused on early stage biotechnology companies in St. Louis, MO. He served as President and CEO of Vasculox (now Arch Oncology) 2010-2015 and Chief Scientific Officer 2015-2017 after the company attracted venture capital investors.
Michael A. Tones, PhD
Chief Scientific Officer
Dr. Tones’ pharmaceutical and start-up medical device company experience comprises nearly 30 years of R&D project leadership from Discovery to Clinical Development stages. Having worked for Ciba Pharmaceuticals and Pfizer in the UK, Switzerland and the US, Dr. Tones is a biochemist by training and a translational pharmacologist by vocation, contributing to the identification of novel compound classes and drug repositioning opportunities in cardiovascular, neurological, metabolic and rare disease areas. Dr. Tones has been PI on several small business grant projects and serves on the BioGenerator mock review panel for SBIR/STTR applications.
Kathleen L. Beckmann
Chief Financial Officer
Kathleen Beckmann is an experienced financial executive who has worked in biotech, finance, and consumer advocacy. She has expertise in finance, operations, business development, human resources and SBIR grant management. Ms. Beckmann has spent the last nine years as the CFO for multiple rapidly growing biotech companies in Saint Louis including Vasculox (now Arch Oncology) and Euclises Pharmaceuticals. Prior to this Ms. Beckmann conducted business development for the Consumer Reports Buy Drugs™ prescription drugs information program and worked in senior managerial roles for multiple Fortune 500 banks in New York City. She has an MBA from Stanford and a BA from Princeton.
Who We’re Looking For
Cadre Bioscience seeks partnerships with scientific inventors who have a therapeutic technology with the potential for commercial development. We are a plug-and-play model for early-stage therapeutics, providing an accelerated process that is ready for immediate implementation. The team, facilities and resources are all in place. Cadre take responsibility for day-to-day operations, raising capital and developing and implementing a sound commercialization plan.
By partnering with Cadre, inventors can retain their focus on scientific innovation instead of spending time learning the legal, financial and operational aspects of founding and running a business. We very much encourage you to continue to work with us in an advisory role so that your deep knowledge and understanding can combine with our business and industry experience.